US-based biotechnology company Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Adicet Bio ( (ACET) ) has issued an update.

Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at the 2024 annual meeting of the Society of Urologic ...

Source: Getty Images Phase 1 results support further evaluation of ALLO-316 in patients with CD70-positive clear cell renal cell carcinoma ... in the phase 1 TRAVERSE trial (NCT04696731), which ...

Management of advanced renal cell carcinoma remains a persistent clinical challenge with high morbidity and mortality for a large proportion of patients. Until recently, available medical ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Kidney Cancer Session II. Dr Mark Ball discussed ...

NEC Bio presents positive interim results from phase 1 trial of NECVAX-NEO1, an AI-driven personalized oral cancer vaccine, at ESMO Congress 2024: Tokyo, Japan Friday, December 13 ...

These cystic tumors are extremely difficult to distinguish based on clinical, radiological, and gross features, and they can cause a diagnostic dilemma. Cystic renal cell carcinoma is a ...